[1]任蕾 夏芳芳 戴红艳.血管生成素样蛋白6在心血管病方面的研究进展[J].心血管病学进展,2020,(4):388-390.[doi:10.16806/j.cnki.issn.1004-3934.20.04.015]
　REN Lei,XIA FangFang,DAI HongYan.Relationship Between ANGPTL6 and Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2020,(4):388-390.[doi:10.16806/j.cnki.issn.1004-3934.20.04.015]
点击复制

血管生成素样蛋白6在心血管病方面的研究进展
()
分享到：

《心血管病学进展》[ISSN:51-1187/R/CN:1004-3934]

卷:
期数:
2020年4期
页码:
388-390
栏目:
综述
出版日期:
2020-04-25

文章信息/Info

Title:
Relationship Between ANGPTL6 and Cardiovascular Disease
作者:
任蕾 夏芳芳 戴红艳
(青岛大学附属青岛市市立医院心血管内科山东 青岛 266000)
Author(s):
REN Lei;  XIA FangFang;  DAI HongYan
(Department of CardioQingdao Municipal Hospital Affiliated to Qingdao University,Qingdao 266000,Shandong,China)
关键词:
血管生成素生因子; 血管生成; 胰岛素抵抗; 代谢综合征; 心血管疾病
Keywords:
Angiopoietin-related Growth Factor; Angiogenesis; Insulin resistance; Metabolic syndrome; Cardiovascular disease
DOI:
10.16806/j.cnki.issn.1004-3934.20.04.015
摘要:
血管生成素样蛋白（ANGPTL6）作为一种肝细胞源蛋白因子，能增加能量消耗抵抗肥胖；改善胰岛素敏感，降低胰岛素抵抗；促进表皮细胞再生；参线粒体氧化磷酸化调节；同时改善缺血小鼠肢体再灌注，大大降截肢风险，减远期心血管并发症风险。许多研究提出ANGPTL6糖尿病、肥胖代谢综合征具有早期预测作用，在下肢动脉疾病子痫患者血清中表达。就其心血管疾病相互关系一综述。
Abstract:
Angiogenin-like protein 6(ANGPTL6) as a hepatocellular protein factor can increase energy consumption to combat obesity,improve insulin sensitivity,reduce insulin resistance,promote epidermal cell regeneration and it is involved in the regulation of mitochondrial oxidative phosphorylation.It also improves limb reperfusion in ischemic mice,greatly reduces the risk of amputation and long-term cardiovascular complications.Many studies have proposed that ANGPTL6 plays an early predictive role in diabetes,obesity and metabolic syndrome,and significantly is increased in serum of patients with lower extremity artery diseases and eclampsia.This article reviews the relationship between ANGPTL6 and cardiovascular diseases.

参考文献/References:

[1].Ruiz-García AArranz-Martínez E,García-?lvarez J C,et al. Population and methodology of the SIMETAP study:Prevalence of cardiovascular risk factors,cardiovascular diseases,and related metabolic diseases[J].Clin Investig rterioscler,2018,30(5):197-208.
[2].Caland L,Labbé P,Mamarbachi M,et al. Knockdown of angiopoietin-like 2 induces clearance of vascular endothelial senescent cells by apoptosis,promotes endothelial repair and slows atherogenesis in mice Aging[J].Albany NY,2019,11(11):3832-3850
[3].Lang W,Frishman WH. Angiopoietin-like 3 Protein Inhibition:A New Frontier in Lipid Lowering Treatment[J].Cardiol Rev,2019,27(4):211-217.
[4].Li Y,He PP,Zhang DW,et al. Lipoprotein lipase:from gene to atherosclerosis[J]. Atherosclerosis,2014,237:597-608.
[5].Aryal B,Price N L,Suarez Y,et al. ANGPTL4 in metabolic and cardiovascular disease[J]. Trends Mol Med,2019,25(8):723-734.
[6].Kovrov O,Kristensen KK,Larsson E,et al. The mechanism of angiopoietin-like protein 8 for control of lipoprotein lipase activity[J]. J Lipid Res,2019,60(4):783-793.
[7].Ehrlich KC,Lacey M,Ehrlich M,et al. Tissue-specific epigenetics of atherosclerosis-related ANGPT and ANGPTL genes[J]. Epigenomics 2019,11(2):169-186.
[8].龚珂,佘强. Betatrophin在冠心病中的研究进展[J]. 心血管病学展,2019,40(2):231-234.
[9]. Oike Y,Yasunaga K,Ito Y,et al. Angiopoietin-related growth factor(AGF) promotes epidermal proliferation,remodeling,and regeneration[J]. PNAS,2003,100(16)9494-9499.
[10].Oike Y,Yasunaga K,Suda T.et al. Angiopoietin-related/angiopoietin-like proteins regulate angiogenesis[J]. Int J Hematol,2004,80(1):21-28.
[11].Stefano R,Yin W,Kozlitina J,et al. Rare loss-of-function mutations in ANGPTL family members contribute to plasma triglyceride levels in humans[J]. J Clin Invest,2009,119 (1):70-79.
[12]. Akhter S,Rahman MM,Lee HS,et al. Angiopoietin-like proteins 1,2,3,4,6 and 7 in the survival and enhancement of exvivo expansion of bone-marrow hematopoietic stem[J]. Protein Cell,2013,4(3):220-230.
[13]. Oike Y,Tabata M. Angiopoietin-like proteins potential therapeutic targets for metabolic syndrome and cardiovascular disease[J]. Circ J,2009,73(12):2192-2197.
[14].Chen E,Tang C,Peng K,et al. ANGPTL6-mediated angiogenesis promotes alpha fetoprotein-producing gastric cancer progression[J]. Pathol Res Pract,2019,215(8):152454.
[15]. Kadomatsu T,Tabata M,Oike Y.et al. Angiopoietin-like proteins:emerging targets for treatment of obesity and related metabolic diseases[J]. The FEBS J,2011,278(4):559-564.
[16].Legry V,Goumidi L,Huyvaert M,et al. Association between angiopoietin-like 6(ANGPTL6) gene polymorphisms and metabolic syndrome-related phenotypes in the French MONICA Study[J]. Diabetes Metab,2009,35(4):287-292.
[17]. Namkung J,Sohn JH,Chang JS,et al. Increased serum angiopoietin-like6 ahead of metabolic syndrome in a prospective cohort study[J]. Diabetes Metab J,2019,43(4):521-529.
[18].Sarwar N,Gao P,Seshasai SR,?et al.Emerging Risk Factors Collaboration, Diabetes mellitus,fasting blood glucose concentration,and risk of vascular disease:a collaborative meta-analysis of 102 prospective studies[J]. Lancet,2010,375(9733):2215-2222.
[19].Oike Y,Akao M,Kubota Y,et al. Angiopoietin-like proteins:potential new targets for metabolic syndrome therapy[J]. Trends Mol Med,2005,11(10):473-482.
[20].Oike Y,Akao M,Yasunagak,et al. Angiopoietin-related growth factor antagonizes obesity and insulin resistance[J]. Nat Med,2005,11(4):400-408.
[21].Kitzawa M,Ohizumi Y,Oike Y,et al. Angiopoietin-related growth factor suppresses gluconeogenesis through the Akt/forkhead box class O1-dependent pathway in hepatocytes[J]. J Pharmacol Exp Ther,2007,323(3):787-793.
[22].Erkan G,Muratoglu S,Ercin U,et al. Angiopoietin-like protein 2 and angiopoietin-like protein6 levels in patients with nonalcoholic fatty liver disease[J]. Arch Med Sci,2018,14(4):781-787.
[23].Kim MJ,Namkung J,Chang JS,et al. Leptin regulates the expression of angiopoietin-like 6[J]. Biochem Biophys Res Commun,2018,502(3):397-402.
[24]. Signore AP,Zhang F,Weng Z,et al. Leptin neuroprotection in the CNS:mechanisms and therapeutic potentials[J]. Neurochem,2008,106(5):1977-1990.
[25].Beltowski J. Leptin and atherosclerosis.Atherosclerosis[J]. 2006,189(1):47-60.
[26].Du Q,Yang DB,Shen YF,et al. Plasma leptin level predicts hematoma growth and early neurological deterioration after acute intracerebral hemorrhage[J]. Peptides,2013,45:35-39.
[27].Khafaji HARH,Bener AB,Rizk NM,et al. Elevated serum leptin levels in patients with acute myocardial infarction; correlation with coronary angiographic and echocardiographic findings[J]. BMC Res Notes,2012,5(1):262.???
[28].Gasbarrino K,Mantzoros C,Gorgui J,et al. Circulating chemerin is associated with carotid plaque instability,whereas resistin is related to cerebrovascular symptomatology[J]. Arterioscler Thromb Vasc Biol,2016,36(8):1670-1678.
[29].Domouzoglou EM,Naka KK,Vlahos AP,et al. Fibroblast growth factors in?cardiovascular disease:The emerging role of FGF21[J]. Physiol Heart Circ Physiol,2015,309 (6):1029-1038.
[30].Kang SG,Yi HS,Choi MJ,et al. ANGPTL6 expression is coupled with mitochondrial OXPHOS function to regulate adipose FGF21[J]. J Endocrinol,2017,233(1):105-118.
[31].Kaimoto S,Hoshino A,Ariyoshi M,et al. Activation of PPAR-α in the early stage of heart failure maintained myocardial function and energetics in pressure-overload heart failure[J]. Am J Physiol Heart Circ Physiol,2017,312(2):305-313.
[32]. Bourcier R,Scouarnec SL,Bonnaud S,et al. Rare Coding Variants in ANGPTL6 Are Associated with Familial Forms of Intracranial Aneurysm[J]. Am J Hum Genet,2018,102(1):133-141.
[33].Sane DC,Anton L,Brosnihan KB,et al. Angiogenic growth factors and hypertension[J]. Angiogenesis,2004,7(3):193-201.
[34].Tuuri AL,Jauhiainen MS,Ehnholm CP,et al. Elevated serum angiopoietin-like protein 6 in women with subsequent pregnancy-induced hypertension:a preliminary study[J]. Hypertens Pregnancy,2013,32(3):203-213.
[35].Xia G,Fang M,He Y,Zhang T,et al. Alterations of angiopoietin-related growth factor(Angptl6) during pregnancy and in pre-eclampsia[J]. J Obstet Gynaecol Res,2013,39(6):1137-1141.
[36].Stepan H,Ebert T,Schrey 2,et al. Serum levels of angiopoietin-related growth factor are increased in preeclampsia[J]. Am J Hypertens,2009,22:314-318.
[37]. Urano T,Ito Y,Akao M,et al. Angiopoietin-related growth factor enhances blood flow via activation of the ERK1/2-eNOS-NO pathway in a mouse hind-limb ischemia model[J]. Arterioscler Thromb Vasc Biol,2008,28(5):827-834.
[38].Nie H,Liang Y,Wang HW,et al. Angiopoietin-related growth factor is independently associated with lower extremity peripheral arterial disease[J]. J Diabetes Complications,2017,31(12):433-438.

相似文献/References:

[1]魏士雄 孙赫.过氧化物酶体增殖物激活受体激动剂在心肌梗死中的作用机制研究进展[J].心血管病学进展,2021,(12):1110.[doi:10.16806/j.cnki.issn.1004-3934.2021.12.013]
　WEI Shixiong,SUN He.Action Mechanism of Peroxisome Proliferator-activated Receptor Agonist in Myocardial Infarction[J].Advances in Cardiovascular Diseases,2021,(4):1110.[doi:10.16806/j.cnki.issn.1004-3934.2021.12.013]
[2]谢佳佳 廖文君 吴碧君 唐其东 李瑜辉.三突变型氧诱导因子α对老年小鼠缺血后肢的促血管作用[J].心血管病学进展,2022,(9):841.[doi:10.16806/j.cnki.issn.1004-3934.2022.09.017]
　XIE Jiajia,LIAO Wenjun,WU Bijun,et al.Neovascularization Effects of Triple-Point Mutant Hypoxia-Inducible Factor-1 on Ischemic Hindlimbs of Aged Mice[J].Advances in Cardiovascular Diseases,2022,(4):841.[doi:10.16806/j.cnki.issn.1004-3934.2022.09.017]
[3]王一彪 王衍 刘雨薇 缪黄泰 曾玉杰.急性心肌梗死患者冠状动脉侧支循环的研究进展[J].心血管病学进展,2023,(5):389.[doi:10.16806/j.cnki.issn.1004-3934.2023.05.002]
　WANG YibiaoWANG YanL IU Yuwei MIAO HuangtaiZENG Yujie.Collateral Circulation of Coronary Artery in Patients with Acute Myocardial Infarction[J].Advances in Cardiovascular Diseases,2023,(4):389.[doi:10.16806/j.cnki.issn.1004-3934.2023.05.002]

备注/Memo

备注/Memo:
基金项目：山东省青岛市科技局项目（17-3-3-30-nsh）
通讯作者：戴红艳，E-mail：daihy9@163.com
收稿日期：2019-07-29
更新日期/Last Update: 2020-07-28